Tag Archives: Gilotrif

October, 2018

19 October
Study Shows using Giotrif/Gilotrif Followed by Osimertinib Provides a Median of 27.6 Months of Chemotherapy-Free Time in Patients with NSCLC

INGELHEIM, Germany–(BUSINESS WIRE)–Boehringer Ingelheim today announced results from GioTag, a real-world retrospective study which examined the impact of first-line Giotrif®/Gilotrif® (afatinib) followed by osimertinib, in epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer (NSCLC) patients with acquired T790M mutations, the most common mechanism of resistance to first- and …
Share

19 January
QIAGEN Receives FDA Approval to Expand Use of EGFR Test in Non-Small Cell Lung Cancer

Germantown, Maryland, and Hilden, Germany, January 18, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has approved a PMA supplement extending the indications for use of QIAGEN’s therascreen® EGFR RGQ PCR Kit as a companion diagnostic to guide the use …
Share
16 January
FDA Approves New Indication for Boehringer Ingelheim’s Gilotrif in EGFR Mutation-Positive Non-Small Cell Lung Cancer

RIDGEFIELD, Conn., Jan. 16, 2018 /PRNewswire/ — Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Gilotrif® (afatinib) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor …
Share

18 April
FDA Approves Boehringer Ingelheim’s Gilotrif as new Oral Treatment for Squamous Cell Carcinoma of the Lung

RIDGEFIELD, Conn., April 15, 2016 /PRNewswire/ — Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Gilotrif® (afatinib) tablets for the treatment of patients with advanced squamous cell carcinoma of the lung whose disease has progressed after treatment …
Share